ESH 2017 | The rapid progression of IDH1/2 mutant enzyme inhibitors through clinical trials
Stéphane de Botton
• 5 Oct 2017
In this video, Stéphane de Botton, MD, PhD of the Gustave Roussy Institute, Villejuif, France, describes the rapid progression of IDH1/2 mutant inhibitors through clinical trials for the potential treatment of acute myeloid leukemia. Despite these mutations only being discovered in 2009, the IDH2 inhibitor drug, enasidenib has already been FDA approved. In this video, Dr de Botton discusses the reasons behind this success, namely the very high response rates experienced, as well as the complications they were anticipating. This video was recorded at the International Conference on Acute Myeloid Leukaemia 2017, Estoril, Portugal by the European School of Haematology (ESH).
